Objective  To evaluate the efficacy, safety and economy of inclisiran in the treatment of dyslipidemia by rapid health technology assessment, and to provide evidence-based basis for clinical treatment.

Methods  PubMed, Web of Science, Embase, Cochrane Library, CNKI, WanFang Data, VIP, SinoMed databases, and official websites of health technology assessment (HTA) institutions were systematically searched to collect HTA reports, systematic reviews/Meta-analysis and pharmacoeconomic studies on inclisiran for the treatment of dyslipidemia from inception to December 31, 2024. Two researchers independently screened the literature, extracted information and performed quality assessment of the included literature, and then qualitative synthesis and analysis of the findings were conducted.

Results  A total of 8 studies were included, comprising 7 systematic reviews/Meta-analysis and 1 pharmacoeconomic study. In terms of efficacy, inclisiran significantly reduced low-density lipoprotein cholesterol, apolipoprotein B, total cholesterol, triglycerides and non-high-density lipoprotein cholesterol levels in patients with dyslipidemia compared to placebo. In terms of safety, the incidence of adverse drug reactions associated with inclisiran did not differ significantly from that of placebo, with the most common adverse drug reactions being mild injection site reactions. In terms of cost-effectiveness, the current price of inclisiran made its combination therapy with statins economically unfavorable compared to statin monotherapy.

Conclusion  The efficacy and safety of inclisiran in the treatment of dyslipidemia are good. However, due to its current pricing, the combination therapy of inclisiran with statins is not yet cost-advantageous compared to statin monotherapy in clinical  practice.

1.Wen W, Fan H, Zhang S, et al. Associations between metabolic dysfunction-associated fatty liver disease and atherosclerotic cardiovascular disease[J]. Am J Med Sci, 2024, 368(6): 557-568. DOI: 10.1016/j.amjms.2024.06.022.

2.Sotler T, Sebestjen M. PCSK9 as an atherothrombotic risk factor[J]. Int J Mol Sci, 2023, 24(3): 1966. DOI: 10.3390/ijms24031966.

3.毕龙飞, 刘瑶, 余丹, 等. 阿利西尤单抗对急性心肌梗死患者PCI术后有效性和安全性的Meta分析[J]. 数理医药学杂志, 2024, 37(10): 761-774. [Bi LF, Liu Y, Yu D, et al. Efficacy and safety of alirocumab after PCI in patients with acute myocardial infarction: a Meta-analysis[J]. Journal of Mathematical Medicine, 2024, 37(10): 761-774.] DOI: 10.12173/j.issn.1004-4337.202405144.

4.Frampton JE. Inclisiran: a review in hypercholesterolemia[J]. Am J Cardiovasc Drugs, 2023, 23(2): 219-230. DOI: 10.1007/s40256-023-00568-7.

5.Gallego-Colon E, Daum A, Yosefy C. Statins and PCSK9 inhibitors: a new lipid-lowering therapy[J]. Eur J Pharmacol, 2020, 878: 173114. DOI: 10.1016/j.ejphar.2020.173114.

6.German CA, Shapiro MD. Small interfering RNA therapeutic inclisiran: a new approach to targeting PCSK9[J]. BioDrugs, 2020, 34(1): 1-9. DOI: 10.1007/s40259-019-00399-6.

7.Albosta MS, Grant JK, Taub P, et al. Inclisiran: a new strategy for LDL-C lowering and prevention of atherosclerotic cardiovascular disease[J]. Vasc Health Risk Manag, 2023, 19: 421-431. DOI: 10.2147/VHRM.S338424.

8.Lamb YN. Inclisiran: first approval[J]. Drugs, 2021, 81(3): 389-395. DOI: 10.1007/s40265-021-01473-6.

9.Katsiki N, Vrablik M, Banach M, et al. Inclisiran, low-density lipoprotein cholesterol and lipoprotein (a)[J]. Pharmaceuticals (Basel), 2023, 16(4): 577. DOI: 10.3390/ph16040577.

10.Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial[J]. Lancet, 2014, 383(9911): 60-68. DOI: 10.1016/S0140-6736(13)61914-5.

11.Wang X, Wen D, Chen Y, et al. PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network Meta-analysis[J]. Cardiovasc Diabetol, 2022, 21(1): 107. DOI: 10.1186/s12933-022-01542-4.

12.Rajendran Y, Nandhakumar M, Eerike M, et al. A comparative analysis of low-density lipoprotein cholesterol (LDL-C)-lowering activities of bempedoic acid, inclisiran, and PCSK9 inhibitors: a systematic review[J]. Cureus, 2024, 16(9): e69900-e69900. DOI: 10.7759/cureus.69900.

13.Asbeutah AAA, Asbeutah SA, Abu-Assi MA. A Meta-analysis of cardiovascular outcomes in patients with hypercholesterolemia treated with inclisiran[J]. Am J Cardiol, 2020, 128: 218-219. DOI: 10.1016/j.amjcard.2020.05.024.

14.Burnett H, Fahrbach K, Cichewicz A, et al. Comparative efficacy of non-statin lipid-lowering therapies in patients with hypercholesterolemia at increased cardiovascular risk: a network Meta-analysis[J]. Curr Med Res Opin, 2022, 38(5): 777-784. DOI: 10.1080/03007995.2022.2049164.

15.Zhou W, Liang Z, Lou X, et al. The combination use of inclisiran and statins versus statins alone in the treatment of dyslipidemia in mainland China: a cost-effectiveness analysis[J]. Front Pharmacol, 2024, 15: 1283922. DOI: 10.3389/fphar.2024.1283922.

16.喻芳, 曾露, 魏安华, 等. 依达拉奉治疗急性缺血性脑卒中的快速卫生技术评估[J]. 药物流行病学杂志, 2024, 33(10): 1147-1155. [Yu F, Zeng L, Wei AH, et al. Edaravone in the treatment of acute ischemic stroke: a rapid health technology assessment[J]. Chinese Journal of Pharmacoepidemiology, 2024, 33(10): 1147-1155.] DOI: 10.12173/j.issn.1005-0698. 202407022.

17.Hailey D. Toward transparency in health technology assessment: a checklist for HTA reports[J]. Int J Technol Assess Health Care, 2003, 19(1): 1-7. DOI: 10.1017/s0266462303000011.

18.张方圆, 沈傲梅, 曾宪涛, 等. 系统评价方法学质量评价工具AMSTAR 2解读[J]. 中国循证心血管医学杂志, 2018, 10(1): 14-18. [Zhang FY, Shen AM, Zeng XT, et al. An introduction to AMSTAR 2: a critical appraisal tool for systematic reviews[J]. Chinese Journal of Evidence-Based Cardiovascular Medicine, 2018, 10(1): 14-18.] DOI: 10.3969/j.issn.1674-4055.2018.01.03.

19.Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS Ⅱ good practices task force[J]. Value Health, 2022, 25(1): 10-31. DOI: 10.1016/j.jval.2021.10.008.

20.Liu D, Zhang J, Zhang X, et al. The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in patients with hypercholesterolemia: a network Meta-analysis[J]. Front Cardiovasc Med, 2024, 11: 1454918. DOI: 10.3389/fcvm.2024.1454918.

21.俞赟丰, 周曼丽, 罗晓欣, 等. Inclisiran治疗高胆固醇血症的荟萃分析和试验序贯分析[J]. 中国循证心血管医学杂志, 2023, 15(9): 1030-1035, 1046. [Yu YF, Zhou ML, Luo XX, et al. Meta analysis and trial sequential analysis on inclisiran in treatment of hypercholesterolemia[J]. Chinese Journal of Evidence-Based Cardiovascular Medicine, 2023, 15(9): 1030-1035, 1046.] DOI: 10.3969/j.issn.1674-4055.2023.09.02.

22.Khan SA, Naz A, Masood MQ, et al. Meta-analysis of inclisiran for the treatment of hypercholesterolemia[J]. Am J Cardiol, 2020, 134: 69-73. DOI: 10.1016/j.amjcard.2020.08.018.

23.Toth PP, Bray S, Villa G, et al. Network Meta-analysis of randomized trials evaluating the comparative efficacy of lipid-lowering therapies added to maximally tolerated statins for the reduction of low-density lipoprotein cholesterol[J]. J Am Heart Assoc, 2022, 11(18): e025551. DOI: 10.1161/JAHA.122.025551.

24.Zhang S, Sun L, Xu X, et al. Efficacy and safety of inclisiran versus PCSK9 inhibitor versus statin plus ezetimibe therapy in hyperlipidemia: a systematic review and network Meta-analysis[J]. BMC Cardiovasc Disord, 2024, 24(1): 629. DOI: 10.1186/s12872-024-04321-z.

25.Huang YT, Ho LT, Hsu HY, et al. Efficacy and safety of proprotein convertase subtilisin/kexin type 9 inhibitors as adjuvant treatments for patients with hypercholesterolemia treated with statin: a systematic review and network Meta-analysis[J]. Front Pharmacol, 2022, 13: 832614. DOI: 10.3389/fphar.2022.832614.

26.Banach M, Reiner Ž, Surma S, et al. 2024 recommendations on the optimal use of lipid-lowering therapy in established atherosclerotic cardiovascular disease and following acute coronary syndromes: a position paper of the International Lipid Expert Panel (ILEP)[J]. Drugs, 2024, 84(12): 1541-1577. DOI: 10.1007/s40265-024-02105-5.

27.王增武, 郭远林. 中国血脂管理指南（基层版2024年） [J]. 临床心血管病杂志, 2024, 40(4): 249-256. [Wang ZW, Guo YL. Chinese guideline for lipid management (primary care version 2024[J]. Journal of Clinical Cardiology, 2024, 40(4): 249-256.] DOI: 10.13201/j.issn.1001-1439.2024.04.001.

28.Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee[J]. J Am Coll Cardiol, 2022, 80(14): 1366-1418. DOI: 10.1016/j.jacc.2022.07.006.

29.Wright RS, Raal FJ, Koenig W, et al. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial[J]. Cardiovasc Res, 2024, 120(12): 1400-1410. DOI: 10.1093/cvr/cvae109.